These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29311047)

  • 1. Cutaneous drug Reactions: Chemotherapy-induced hyperpigmentation.
    Hernández-Aragüés I; Baniandrés-Rodríguez O; Vilas-Boas PT; Conde-Montero E; Suárez-Fernández R
    Eur J Dermatol; 2017 Dec; 27(6):679-680. PubMed ID: 29311047
    [No Abstract]   [Full Text] [Related]  

  • 2. Hope for very elderly patients with diffuse large B-cell lymphoma.
    Ribera JM
    Lancet Oncol; 2011 May; 12(5):412-3. PubMed ID: 21482185
    [No Abstract]   [Full Text] [Related]  

  • 3. HBV reactivation in immunosuppressed patients: prevention or containment?
    Ludwig E
    Hepatology; 2014 Jun; 59(6):2062-4. PubMed ID: 24753022
    [No Abstract]   [Full Text] [Related]  

  • 4. Hidden superpower.
    McGuirt J
    JAAPA; 2019 May; 32(5):66. PubMed ID: 31033720
    [No Abstract]   [Full Text] [Related]  

  • 5. [Risk of reactivation of hepatitis B in patients with the lymphoma HBsAg negative , anti-HBc positive treated with rituximab-CHOP].
    Pariente A
    Rev Prat; 2014 Mar; 64(3):324. PubMed ID: 24851363
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic polymorphism at
    Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
    Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
    [No Abstract]   [Full Text] [Related]  

  • 7. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
    Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
    Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness.
    Hay AE; Meyer RM
    J Clin Oncol; 2012 Sep; 30(26):3155-7. PubMed ID: 22891267
    [No Abstract]   [Full Text] [Related]  

  • 11. Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.
    Schulte-Huermann P; Zumdick M; Ruzicka T
    Dermatology; 1995; 191(1):65-7. PubMed ID: 8589490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma.
    Palmowski M; Zechmann C; Satzl S; Bartling S; Hallscheidt P
    Ann Hematol; 2008 Apr; 87(4):337-8. PubMed ID: 17929016
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of chemotherapy in extremely elderly patients with diffuse large B-cell lymphoma].
    Takahashi A; Mishima Y; Yokoyama M; Inoue N; Kusano Y; Gunji T; Nitta H; Ueda K; Nishimura N; Tsuyama N; Takeuchi K; Terui Y; Hatake K
    Rinsho Ketsueki; 2017; 58(5):427-432. PubMed ID: 28592754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):15-6. PubMed ID: 27007007
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of BAX G(-248)A and BCL2 C(-717)A polymorphisms with outcome in diffuse large B-cell lymphoma patients.
    Brito ABC; Delamain MT; de Oliveira C; Fanelli MF; Soares FA; de Souza CA; Vassallo J; Silvia Passos Lima C
    Br J Haematol; 2017 May; 177(4):650-654. PubMed ID: 27098707
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
    Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
    Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
    Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
    J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.